Lupin advances on receiving EIR from USFDA

Lupin has received the Establishment Inspection Report (EIR) from the US drug regulator upon completion of inspection of its facility in Tarapur, Maharashtra. The inspection was conducted between August 27 and August 31, 2018 concluded with one observation.

Founded in 1992, the Tarapur facility is a state-of-the-art unit for manufacturing Active Pharmaceuticals Ingredients (API), both through fermentation-based and synthetic processes.

Last one week high and low of the scrip stood at Rs. 857.40 and Rs. 834.10, respectively. The current market cap of the company is Rs. 38,533.08 crore.

The promoters holding in the company stood at 47.00 per cent, while Institutions and Non-Institutions held 37.69 and 15.30 per cent, respectively.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biotechnology products and APIs, globally.

On Tuesday's trade, the stock has opened at Rs. 848.70 per share and touched a high/low of Rs. 856.55/Rs. 842.25 and closed at Rs. 849.05 on BSE.